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Summary
Background Atopic dermatitis (AD) disease activity and severity is highly variable
during childhood. Early attempts to identify subtypes based on disease trajectory
have assessed AD presence over time without incorporating severity.
Objectives To identify childhood AD subtypes from symptom severity and trajecto-
ries, and determine associations with genetic risk factors, comorbidities and
demographic and environmental variables.
Methods We split data from children in the Avon Longitudinal Study of Parents
and Children birth cohort into development and validation sets. To identify sub-
types, we ran latent class analyses in the development set on AD symptom
reports up to age 14 years. We regressed identified subtypes on nongenetic vari-
ables in mutually adjusted, multiply imputed (genetic: unadjusted, complete
case) multinomial regression analyses. We repeated analyses in the validation set
and report confirmed results.
Results There were 11 866 children who contributed to analyses. We identified one
Unaffected/Rare class (66% of children) and four AD subtypes: Severe–Frequent
(4%), Moderate–Frequent (7%), Moderate–Declining (11%) and Mild–Intermittent
(12%). Symptom patterns within the first two subtypes appeared more homoge-
neous than the last two. Filaggrin (FLG) null mutations, an AD polygenic risk score
(PRS), being female, parental AD and comorbid asthma were associated with higher
risk for some or all subtypes; FLG, AD-PRS and asthma associations were stronger
along a subtype gradient arranged by increasing severity and frequency; FLG and AD-
PRS further differentiated some phenotypes from each other.
Conclusions Considering severity and AD trajectories leads to four well-defined and
recognizable subtypes. The differential associations of risk factors among and
between subtypes is novel and requires further research.
What’s already known about this topic?
• Atopic dermatitis (AD) is a heterogeneous condition in terms of both disease activ-
ity and severity.
• Childhood AD phenotypes in previous studies have focused only on disease activ-
ity.
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What does this study add?
• We incorporate disease severity over time to derive four clinically recognizable AD
phenotypes using data-driven methods.
• Disease severity improved over time in all phenotypes (even in those with high
probability of activity in late childhood and adolescence).
• Several established risk factors, including genetic associates, were associated with
our proposed phenotypes, with most factors more strongly associated with pheno-
types reporting the worst symptoms. Fewer factors differentiated between more
Frequent and Declining/Intermittent phenotypes.
Atopic dermatitis (AD) (eczema) is characterized by considerable
heterogeneity including clinical morphology, disease severity,
age at presentation, disease course and comorbidities. Many
attempts have been made to address this heterogeneity by identi-
fying AD subtypes, which may improve diagnosis, more accu-
rately estimate clinical prognoses, inform management or better
predict treatment efficacy or effectiveness.1 In older literature AD
is largely subtyped into allergic and nonallergic forms; recent evi-
dence suggests that this dichotomization is not clinically useful2
because IgE levels or sensitization status alone do not predict
symptom resolution or treatment response.3 Recent efforts using
longitudinal cohorts have attempted to identify AD subtypes
from trajectories of childhood disease activity4–6 or patterns of
atopic disease overall.7–10 However, none of these categoriza-
tions account for disease severity, which is the primary predictor
of quality of life, sleep disruption, comorbidities including men-
tal health outcomes, and need for systemic treatments.11,12 Iden-
tifying factors early in the disease course that could differentiate
between mild but persistent cases and severe but resolving cases
is important both for understanding aetiology and outcomes and
for informing patient prognoses and treatment options.
In this paper, we aim to identify AD subtypes based on tra-
jectories of flexural dermatitis in children related to both pres-
ence and severity of disease, and quantify their relationships
with known and suspected AD risk factors. We note that sub-
types based on disease trajectories over time are not the same
as directly observed phenotypes.13 However, as the term ‘phe-
notypes’ is commonly used to describe AD subtypes, we use
this nomenclature in this paper.
Methods
Study population
We used data from the Avon Longitudinal Study of Parents
and Children (ALSPAC).14,15 Pregnant women resident in
Avon, UK with expected dates of delivery between 1 April
1991 and 31 December 1992 were invited to take part and
14 541 pregnancies were enrolled initially. Of these, there
were 14 676 fetuses, resulting in 14 062 live births and
13 988 children who were alive at 1 year of age, 96% of
whom are of white ethnicity. Please note that the study web-
site contains details of all the data that is available through a
fully searchable data dictionary and variable search tool.16
Atopic dermatitis phenotype determination
AD presence was collected from questionnaires at 11 ages
between 6 and 166 months (138 years). Mothers reported
whether their children experienced flexural dermatitis (FD)
via the International Study of Asthma and Allergies in
Childhood (ISAAC)-validated question:17 ‘Has your child
had an itchy, dry skin rash in the joints and creases of his
body (e.g. behind the knees, elbows, under the arms) in
the past year?’ Participants who responded ‘yes’ were fol-
lowed up with an assessment of self-rated severity, ‘How
bad was this?’ with options: ‘no problem’, ‘mild’, ‘quite
bad’ and ‘very bad’. From these two responses we derived
a five-category severity variable. Participants who did not
complete the questionnaire or did not answer these ques-
tions were coded as ‘missing’.
Other variables
Family history of atopic diseases, environmental exposures
and social class were taken from parental questionnaires dur-
ing pregnancy. Breastfeeding, comorbidities and siblings were
taken from questionnaires at various ages (for definitions see
Methods S1 in the Supporting Information).
Genetic polymorphisms
DNA was obtained from blood samples using standard extrac-
tion techniques.18 In children with genome-wide genotyping
data, we created an AD polygenic risk score (PRS) using the
25 single-nucleotide polymorphisms (SNPs) previously identi-
fied as associated with AD (P < 5 9 10–8),19 where dosage
genotypes were extracted and weighted by the (risk-increas-
ing) genome-wide association study beta coefficient, summed
and standardized to 1 SD.
In children with Filaggrin (FLG) loss-of-function genotyping
data, null mutations in any of R2447X, S3247X, 2282del4 or
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R501X were coded as FLG-present, and FLG-absent was coded
otherwise.
Statistical methods
We randomly split the ALSPAC cohort into two equally sized
groups, one (development cohort) for identifying AD pheno-
types and associated characteristics, and the other (validation
cohort) for internally validating the identified phenotypes. In
both groups we excluded individuals with fewer than two of
the 11 requested FD reports.
Phenotype identification
We identified phenotypes in the development group using
latent class analysis (LCA). FD variables were modelled as joint
categorical outcomes in children with and without FD symp-
toms to allow the LCA to identify a negative control pheno-
type without AD in addition to AD phenotypes.
We ran models with three to eight classes and compared
various model fit statistics (see Methods S1), estimated class
sizes and clinical interpretation (by clinicians with AD man-
agement expertise) to determine the best classification. From
the best fitting model, we estimated individuals’ posterior
class probabilities and identified their most likely phenotype
as the class with the highest probability. We drew heatmaps
for each phenotype showing individuals’ symptom severity
across ages, with a dendrogram to visualize common patterns.
Association of variables with phenotypes
We explored three methods20 to account for phenotype uncer-
tainty (LCA class probabilities) in regression models (Fig-
ure S1; see Supporting Information). We chose the method
that ignores uncertainty and treats phenotypes as known quan-
tities, and report 99% confidence intervals (CIs) to correct for
this method’s potential for overprecision.
We regressed sex, family history of AD, asthma, hay fever, par-
ental education, pet cats and dogs, maternal smoking, breastfeed-
ing (ever and duration), comorbid asthma and older siblings in
the household on phenotypes in unadjusted and mutually
adjusted multinomial regressions. These factors have been previ-
ously associated with AD.21 In the mutually adjusted model, we
excluded ‘ever breastfed’ to avoid collinearity with breastfeeding
duration and additionally adjusted for FLG null mutations to
investigate independence of family history risk factors. We esti-
mated crude genetic risk by regressing FLG, SNPs and the PRS on
AD phenotypes in unadjusted multinomial regressions, treating
SNP and PRS effects as linear.
Phenotype validation
To assess internal validity, we ran the final LCA model in the
validation cohort and visually compared resulting phenotypes
with those from the development cohort. We repeated the
multinomial regressions and qualitatively compared results
with development cohort results.
Missing data handling
We assumed missing FD reports were at random given observed
reports and estimated the LCA using full information maximum
likelihood (FIML). We checked the solution for sensitivity to
departures from this assumption (see Methods S1). We assumed
missing nongenetic regression variables were at random given
observed variables, social class and comorbid hay fever, and used
the multivariate imputation by the chained equations proce-
dure22 to impute them.We ran regression models on 10 imputed
datasets and combined results using Rubin’s rules.23 We per-
formed complete case genetic analyses, assuming genetic data
missingness was completely at random.
Software
LCAs were run in MPlus v8.2 (Muthen & Muthen, Los Ange-
les, CA, USA) and all other analyses in Stata v16.0 (StataCorp,
College Station, TX, USA) and R v3.6.2 (R Foundation for Sta-
tistical Computing, Vienna, Austria).
Ethical approval
Ethical approval for this study was obtained from the ALSPAC
Ethics and Law Committee (B2510) and the London School of




There were 13 972 children born as singletons or twins who
were eligible for inclusion. We randomly allocated half
(n = 6986) to each of the development and validation cohorts.
Within each cohort, 85% had data on FD on two or more ques-
tionnaires (development: 5927; validation: 5939) and were
included in the analyses. In the development and validation
cohorts, respectively, just under half were female (48%/49%);
77%/74% carried a FLG null mutation and 28%/29%, 19%/
18% and 43%/43% had at least one parent with a history of AD,
asthma and hay fever, respectively. All characteristics were bal-
anced between cohorts (Table 1). Reports of FD activity
decreased over time. Generally, the activity peaked at 18 months
while the lowest activity was observed at age 166 months, simi-
lar to the corresponding response rates (92%/91% at 18 months
and 57%/56% at 166 months) (Table S1; see Supporting Infor-
mation).
Atopic dermatitis phenotypes from infancy to
adolescence
From data in the development cohort, we determined the
optimal number of phenotypes from LCA models to be five,
based on the Bayesian information criterion (Results S1 and
Figure S2; see Supporting Information) and clinical inter-
pretability (Figure S3; see Supporting Information). Children
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were generally clearly classified into phenotypes, with high
probability of being in their most likely phenotype (mean 74–
90%) and low probabilities of being in the other four (mean
01–10%) (Figure S4 and Table S2; see Supporting Informa-
tion). There was no evidence the LCA solution was sensitive
to missing data patterns and it was consistent across the devel-
opment and validation cohorts (Figures S5, S6 and Tables S2,
S3; see Supporting Information).
Based on reported severity and duration of FD, we labelled
the classes: Unaffected/Rare, to which 66% of children were
assigned with highest probability, Severe–Frequent AD (4%),
Moderate–Frequent AD (7%), Moderate–Declining AD (11%)
and Mild–Intermittent AD (12%). Children in a particular phe-
notype did not always report the same symptoms as each
other, but heatmaps in children with complete data showed
similar patterns with more consistency among individuals in
each Frequent phenotype than among individuals in the
Declining and Intermittent phenotypes (Figure S7; see Sup-
porting Information).
Figure 1 illustrates the distributions of FD severity at each
age and how they changed over time for each phenotype.
Children in the Severe–Frequent phenotype almost always
reported FD and rarely characterized it as ‘no problem’. For
example, at 6 months of age, FD was present and rated ‘very
bad’ or ‘quite bad’ in 29% of the group, rising to 49% at
18 months, although heterogeneity was present within this
and other subtypes. Children in the Moderate–Frequent phe-
notype also almost always reported FD, although they usually
rated it less severely than children with Severe–Frequent AD
and occasionally rated it as ‘no problem’. Children with
Moderate–Declining AD reported symptoms similar to those
with Moderate–Frequent AD up to age 25 years, but after this
age, their likelihood of FD declined. Children with Mild–Inter-
mittent AD more often reported absence of FD than presence,
and when present usually rated it ‘mild’ or ‘no problem’. Up
to 9% of the Unaffected/Rare group reported FD before age
Table 1 ALSPAC study characteristics
Development cohort
(N = 5927), n (%)
Validation cohort
(N = 5939), n (%)
Sex
Male 3099 (52) 3031 (51)
Female 2828 (48) 2908 (49)
Social classa
I 693 (12) 677 (11)
II 2031 (34) 1999 (34)
III(n) 1203 (20) 1219 (21)
III(m) 387 (65) 414 (7)
IV 113 (19) 125 (21)
V 18 (03) 7 (01)
Missing 1482 (25) 1498 (25)
At least one parent with university degree
No 4393 (74) 4420 (74)
Yes 1288 (22) 1238 (21)
Missing 246 (41) 281 (47)
Parental AD
No 2563 (43) 2557 (43)
Yes 1678 (28) 1700 (29)
Missing 1686 (28) 1682 (28)
Parental asthma
No 2967 (50) 3041 (51)
Yes 1123 (19) 1059 (18)
Missing 1837 (31) 1839 (31)
Parental hay fever
No 1826 (31) 1812 (31)
Yes 2534 (43) 2549 (43)
Missing 1567 (26) 1578 (27)
Any older siblings
No 433 (73) 454 (76)
Yes 2105 (35) 1962 (33)
Missing 3389 (57) 3523 (59)
Pet cat during pregnancy
No 4011 (68) 3965 (67)
Yes 1723 (29) 1778 (30)
Missing 193 (32) 196 (33)
Pet dog during pregnancy
No 4353 (73) 4358 (73)
Yes 1381 (23) 1385 (23)
Missing 193 (32) 196 (33)
Mum smoked during first 3 months of pregnancy
No 4458 (75) 4408 (74)
Yes 1307 (22) 1361 (23)
Missing 162 (27) 170 (29)
Breastfeeding
Never 1409 (24) 1349 (23)
< 3 months 1214 (20) 1240 (21)
3–5 months 855 (14) 908 (15)
6 months + 1857 (31) 1802 (30)
missing 592 (10) 640 (11)
Asthma by 75 years
No 3242 (55) 3188 (54)
Yes 816 (14) 829 (14)
Missing 1869 (31) 1922 (32)
Hay fever by 105 years
No 2877 (48) 2856 (48)
Yes 784 (13) 732 (12)




(N = 5927), n (%)
Validation cohort
(N = 5939), n (%)
FLG null mutation
No 3985 (67) 3891 (66)
Yes 456 (77) 441 (74)
Missing 1486 (25) 1607 (27)
Polygenic risk score (standardized)
Median
(IQR)
–013 (–078 to 063) –010 (–074 to 062)
Missing 1971 (33) 2113 (36)
aI, professional occupations; II, managerial and technical occupa-
tions; III(n), skilled occupations–nonmanual; III(m), skilled
occupations–manual; IV, partly skilled occupations; V, unskilled
occupations. AD, atopic dermatitis; ALSPAC, Avon Longitudinal
Study of Parents and Children; IQR, interquartile range.
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25 years, mostly ‘mild’, but rarely reported it (≤ 3% of the
time) thereafter. Proportions of individuals with missing
symptoms are shown in Figure S8 (see Supporting Informa-
tion).
The distribution of children among phenotypes in the vali-
dation cohort was similar to the distribution in the develop-
ment cohort, except that relatively fewer children were
assigned to the Mild–Intermittent phenotype (8% vs. 12%)
and more to Moderate–Frequent (9% vs. 7%) and Moderate–
Declining (13% vs. 11%) phenotypes.
Variables associated with phenotypes
Table 2 shows the distributions of clinical, demographic and
genetic variables used in the regression analyses by most likely
phenotype.
We used the Unaffected/Rare phenotype as the reference
group in multiple imputation analyses (Table S4; see Support-
ing Information). The unadjusted and adjusted estimates were
similar, except for parental asthma, hay fever and education:
each unadjusted estimate showed a higher risk for all but
Mild–Intermittent AD, which attenuated after adjustment. The
adjusted estimates in the development and validation cohorts
were also similar (Figure 2).
After adjusting for the other variables and FLG, we found
that comorbid asthma, parental AD and sex were associated
with AD phenotype (all P < 00001). Children with asthma
were three times more likely to be in the Severe–Frequent
group [relative risk ratio (RRR) 319, 99% CI (202–506)],
twice as likely to be Moderate–Frequent [RRR 2.07 (145–
297)], and 143 (103–199) and 144 (107–194) times as
likely to be Moderate–Declining and Mild–Intermittent,
respectively. There was strong evidence (P = 00001) for this
differential association with each phenotype. Children with a
family history of AD had twice the risk of Severe–Frequent
[RRR 188 (123–287)] or Moderate–Frequent [RRR 195
(143–266)] disease, 166 (130–212) times the risk of
Moderate–Declining disease and 1.40 (108–181) times the
risk of Mild–Intermittent disease, but there was no evidence
that these associations were truly differential (P = 00987).
Girls were more likely than boys to have Mild–Intermittent
AD [RRR 167 (135–208)]. There was no evidence that the
other variables listed in Table 2 were independently associated
with AD phenotypes.
The patterns of associations above were replicated in the
validation cohort with similar estimates and CIs, except that
differential parental AD RRRs were detectable across pheno-
types (P = 00039). Additionally, in the validation cohort
there was borderline evidence (P = 00063) that maternal
smoking was associated with phenotypes after adjusting for
other variables; there was similar evidence (P = 00135) for
the same association in the development cohort. Children
whose mothers smoked were less likely to have Moderate–Fre-
quent AD in the development cohort and less likely to have
Moderate–Declining AD in the validation cohort; the other
associations were inconclusive.
Figure 1 Atopic dermatitis (AD) phenotypes. Five phenotypes of AD (including an Unaffected/Rare phenotype without AD) identified by latent
class analysis on 5927 ALSPAC children whose mothers responded to at least two questionnaires between the ages of 6 months and 14 years.
Probabilities of flexural dermatitis and its severity are shown by age for children assigned to each phenotype (missing reports not indicated):
Severe–Frequent, n = 230 (39%); Moderate–Frequent, n = 408 (69%); Moderate–Declining, n = 676 (11%); Mild–Intermittent, n = 684 (12%);
Unaffected/Rare, n = 3929 (66%).
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Table 2 ALSPAC development cohort characteristics across each ‘most likely’ atopic dermatitis phenotypea
Severe–Frequent Moderate–Frequent Moderate–Declining Mild–Intermittent Unaffected/Rare
Phenotype, N (%) 230 (39) 408 (69) 676 (11) 684 (12) 3929 (66)
Sex
Male 115 (37) 202 (65) 366 (12) 287 (93) 2129 (69)
Female 115 (41) 206 (73) 310 (11) 397 (14) 1800 (64)
At least one parent with university degree
No 158 (36) 286 (65) 480 (11) 502 (11) 2967 (68)
Yes 63 (49) 113 (88) 170 (13) 164 (13) 778 (60)
Missing 9 (37) 9 (37) 26 (11) 18 (73) 184 (75)
Parental atopic dermatitis
No 73 (28) 138 (54) 278 (11) 296 (12) 1778 (69)
Yes 95 (57) 170 (10) 249 (15) 218 (13) 946 (56)
Missing 62 (37) 100 (59) 149 (88) 170 (10) 1205 (71)
Parental asthma
No 99 (33) 192 (65) 344 (12) 364 (12) 1968 (66)
Yes 61 (54) 99 (88) 155 (14) 124 (11) 684 (61)
Missing 70 (38) 117 (64) 177 (96) 196 (11) 1277 (70)
Parental hay fever
No 56 (31) 106 (58) 198 (11) 232 (13) 1234 (68)
Yes 122 (48) 207 (82) 325 (13) 287 (11) 1593 (63)
Missing 52 (33) 95 (61) 153 (98) 165 (11) 1102 (70)
Any older siblings
No 17 (39) 38 (88) 62 (14) 49 (11) 267 (62)
Yes 86 (41) 168 (8) 248 (12) 285 (14) 1318 (63)
Missing 127 (37) 202 (6) 366 (11) 350 (10) 2344 (69)
Pet cat during pregnancy
No 156 (39) 277 (69) 453 (11) 466 (12) 2659 (66)
Yes 67 (39) 123 (71) 205 (12) 205 (12) 1123 (65)
Missing 7 (36) 8 (41) 18 (93) 13 (67) 147 (76)
Pet dog during pregnancy
No 168 (39) 327 (75) 505 (12) 524 (12) 2829 (65)
Yes 55 (4) 73 (53) 153 (11) 147 (11) 953 (69)
Missing 7 (36) 8 (41) 18 (93) 13 (67) 147 (76)
Mum smoked during first 3 months of pregnancy
No 164 (37) 337 (76) 517 (12) 535 (12) 2905 (65)
Yes 59 (45) 63 (48) 146 (11) 131 (10) 908 (69)
Missing 7 (43) 8 (49) 13 (8) 18 (11) 116 (72)
Breastfeeding
Never 49 (35) 81 (57) 139 (99) 160 (11) 980 (70)
< 3 months 40 (33) 76 (63) 160 (13) 128 (11) 810 (67)
3–5 months 27 (32) 64 (75) 98 (11) 109 (13) 557 (65)
6 months+ 86 (46) 157 (85) 231 (12) 238 (13) 1145 (62)
Missing 28 (47) 30 (51) 48 (81) 49 (83) 437 (74)
Asthma by 75 years
No 96 (3) 211 (65) 360 (11) 417 (13) 2158 (67)
Yes 62 (76) 90 (11) 106 (13) 119 (15) 439 (54)
Missing 72 (39) 107 (57) 210 (11) 148 (79) 1332 (71)
FLG null mutation
No 121 (3) 261 (65) 461 (12) 481 (12) 2661 (67)
Yes 55 (12) 55 (12) 66 (14) 58 (13) 222 (49)
Missing 54 (36) 92 (62) 149 (10) 145 (98) 1046 (70)
Polygenic risk score (standardized)
Median (IQR) 039 (–038 to 147) 018 (–073 to 098) –003 (–074 to 076) –002 (–073 to 064) –022 (–082 to 054)
Missingb 73 (32) 125 (31) 200 (30) 189 (28) 1384 (35)
aAll values are n (%) unless otherwise noted. bMissing polygenic risk scores are tabulated within phenotype, while missingness in other vari-
ables is tabulated across phenotypes. ALSPAC, Avon Longitudinal Study of Parents and Children; IQR, interquartile range.
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Genetic phenotype associates
Of children included in this study, 8773 (74%) had FLG geno-
type data and 7782 (66%) had available genome-wide geno-
type data.
FLG loss-of-function mutations
FLG was strongly associated with AD phenotypes
(P = 426 9 10–32), with strong evidence of higher risks for
more severe and frequently active phenotypes
(P = 123 9 10–10). Children with FLG mutations were more
than four times more likely to have Severe–Frequent AD [RRR
432 (307–607)], more than twice as likely to have Moder-
ate–Frequent AD [RRR 241 (181–322)], 180 (139–234)
times more likely to have Moderate–Declining AD and 152
(113–204) times more likely to have Mild–Intermittent AD
than children without FLG mutations (Table 3).
Standardized genetic score
The PRS was strongly associated with AD phenotypes
(P = 122 9 10–28), with strong evidence of higher risks for
more severe and frequently active phenotypes
Sex (female vs male)
Asthma by 7.5yrs vs none
Parental AD vs none
Parental asthma vs none
Parental hayfever vs none
Parental education (uni degree vs. none)
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Figure 2 Associations of demographic and clinical characteristics with atopic dermatitis phenotypes. Unadjusted and mutually adjusted phenotype
associations in the development cohort (grey and black circles) and adjusted associations in the validation cohort (black triangles). All adjusted
associations include additional adjustment for FLG null mutations. Stated effects and confidence intervals are for adjusted associations in the
development cohort. AD, atopic dermatitis; Adj, adjusted; RRR, relative risk ratio; CI, confidence interval.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2021)
Four childhood AD subtypes, A.R. Mulick et al. 7
(P = 860 9 10–11). A score increase of 1 SD was associated
with a relative risk increase of: 167 (145–193) for Severe–
Frequent, 137 (123–152) for Moderate–Frequent, 117
(107–127) for Moderate–Declining and 113 (102–124)
for Mild–Intermittent AD. Removing rs11205006 from the
score, which tags the FLG locus, and the remainder of the
chromosome 1 SNPs made little difference to these associa-
tions (Table S5; see Supporting Information).
Single-nucleotide polymorphisms
Eight SNPs on chromosomes 1, 6, 11, 14 and 19 were associ-
ated with AD phenotypes (P = 863 9 10–10 to 119 9 10–2;
Table 3). Of these, five were associated with Severe–Frequent
AD (RRR range 131–299), six with Moderate–Frequent
(RRR range 117–207) and one with Moderate–Declining
(RRR 196). There was no evidence that any single SNP was
associated with Mild–Intermittent AD.
Association differences between atopic dermatitis
phenotypes
We explored whether any of the variables we investigated
could distinguish between the four AD phenotypes. In six post-
hoc Bonferroni-corrected pairwise comparisons from the multi-
nomial regression models, we found evidence that the relative
risk associated with asthma, sex, FLG null mutations and the
AD-PRS differed among some phenotype pairs (Table S6; see
Supporting Information). In particular, the AD-PRS and FLG
were able to discriminate between four of six pairs showing a
significantly higher relative risk in the more severe and/or fre-
quently affected phenotypes. The remaining comparisons were





















426E-32 432 (307–607) 241 (181–322) 180 (139–234) 152 (113–204) 123E-10
Polygenic risk
score




994E-07 155 (124–193) 122 (103–144) 111 (097–128) 110 (095–128) 320E-03
rs2228145_c 1 IL6R 369E-04 131 (106–163) 115 (099–134) 095 (083–108) 093 (081–107) 149E-04
rs61813875_g 1 LCE3E,
CRCT1
863E-10 299 (179–498) 207 (134–319) 196 (136–284) 133 (084–209) 982E-03
rs1057258_c 2 INPP5D 581E-02 121 (090–163) 099 (081–121) 097 (082–114) 086 (072–101) 481E-02
rs112111458_a 2 CD207 668E-02 118 (085–165) 100 (080–125) 117 (096–142) 091 (075–110) 442E-02
rs13015714_g 2 IL18R1 540E-02 107 (083–138) 123 (103–147) 106 (092–124) 102 (087–120) 174E-01
rs17389644_a 4 IL21 994E-02 117 (091–151) 107 (089–129) 115 (099–133) 102 (087–121) 436E-01
rs10214237_t 5 IL7R 301E-01 096 (075–121) 106 (089–126) 101 (088–117) 113 (096–132) 366E-01
rs2897442_c 5 KIF3A 478E-02 129 (102–163) 111 (093–132) 099 (086–115) 099 (085–116) 402E-02
rs12153855_t 6 TNXB 875E-03 104 (072–150) 142 (106–191) 107 (086–133) 122 (096–156) 132E-01
rs6473227_c 8 ZBTB10 249E-01 112 (090–140) 109 (093–128) 107 (094–122) 106 (093–122) 947E-01
rs10995251_c 10 ZNF365 582E-01 099 (079–123) 099 (084–116) 108 (095–124) 103 (089–118) 587E-01
rs12295535_t 11 PRR5L 822E-03 155 (092–261) 121 (080–184) 137 (099–191) 078 (050–122) 183E-02
rs479844_g 11 OVOL1 117E-05 151 (121–190) 117 (100–137) 106 (093–121) 106 (092–122) 134E-03
rs7127307_t 11 ETS1 528E-01 105 (084–130) 107 (092–125) 100 (088–113) 107 (094–123) 639E-01
rs7927894_t 11 C11orf30 248E-02 121 (098–150) 109 (094–128) 096 (084–109) 110 (096–126) 374E-02
rs2227483_t 12 IL22 980E-01 103 (083–129) 101 (086–118) 100 (088–114) 103 (090–118) 975E-01
rs2143950_t 14 PPP2R3C 119E-02 124 (095–162) 126 (104–153) 101 (086–120) 106 (089–127) 574E-02
rs7146581_c 14 TRAF3 183E-01 109 (084–142) 116 (096–140) 109 (094–127) 104 (088–122) 678E-01
rs2041733_t 16 CLEC16A 441E-01 098 (079–122) 112 (096–130) 100 (088–114) 103 (090–118) 420E-01
rs11657987_t 17 PGS1 936E-02 122 (099–151) 109 (094–127) 102 (090–115) 106 (092–121) 244E-01
rs16948048_g 17 ZNF652 769E-02 118 (095–146) 092 (079–108) 098 (086–111) 092 (080–106) 550E-02
rs17881320_t 17 STAT3 225E-01 130 (091–186) 112 (085–147) 113 (090–141) 109 (086–139) 737E-01
rs2164983_a 19 ACTL9 126E-05 134 (102–177) 140 (115–170) 116 (098–137) 118 (099–142) 149E-01
rs6010620_g 20 RTEL1 939E-02 114 (088–147) 117 (097–141) 105 (090–121) 111 (094–130) 605E-01
aCompared with the Unaffected/Rare population, n = 4990; bNull hypothesis: RRR1 = RRR2 = RRR3 = RRR4 = 0; cNull hypothesis: RRR1 =
RRR2 = RRR3 = RRR4. ALSPAC, Avon Longitudinal Study of Parents and Children; FLG, Filaggrin gene; SNP, single-nucleotide polymor-
phism; Chr, chromosome; RRR, relative risk ratio; CI, confidence interval.
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inconclusive, generally producing CIs consistent with impor-
tant effects in both directions.
Discussion
We identified four phenotypes of AD based on disease severity
and trajectories during childhood: Severe–Frequent, Moderate–
Frequent, Moderate–Declining and Mild–Intermittent disease.
Healthcare providers and patients might be reassured that in
all subgroups, the probability of reporting ‘quite bad’ or ‘very
bad’ symptoms declined with age (with evidence of within-
group heterogeneity). Associations with some established risk
factors (FLG null mutations, AD-PRS, family history of AD)
and comorbidities (asthma) were present in all phenotypes
with evidence of a gradient of association from more severe
to less severe phenotypes. AD-PRS and FLG mutations were
further able to differentiate many of our phenotypes from
each other, highlighting the need for increased understanding
of drivers of disease severity/activity throughout life in people
with AD, including the role of gene–environment interactions.
Our findings add novel information about patterns of dis-
ease severity over time, and are consistent with prior cross-
sectional studies on disease severity and longitudinal studies
focused on disease activity alone. While disease activity (i.e.
the presence of any symptoms at a particular age) and disease
severity (i.e. the impact of those symptoms) are sometimes
correlated, they are separate concepts, and it is important to
differentiate them.24 For example, a small patch of mild
eczema that persists for years may be quite different from
extensive severe disease that resolves quickly.
Paternoster et al.5 conducted a previous study in ALSPAC
with external validation,25 Hu et al.6 examined a multi-ethnic
population up to age 10 years, and Roduit et al.4 examined a
European population up to age 6 years. All reported pheno-
types described onset timing and persistence during child-
hood, and between them there were some commonly
described phenotypes (early-persistent, early-transient, late-on-
set). Hu et al.6 concluded that established risk factors have little
capacity to differentiate eczema phenotypes. By additionally
incorporating severity, the most clinically relevant aspect of
AD, we have been able to show that genetic factors, in partic-
ular, have the potential to differentiate between phenotypes.
Our study has several strengths. We used a well-character-
ized, population-based cohort; hence, our results are general-
izable to similar settings and populations. Our large sample
(n = 11 866) offered precision, and our phenotypes were
internally reproducible, lending confidence to our findings.
We applied robust statistical methods to minimize imprecision
and bias in our regression estimates.
Our study also has limitations. We used a measure of self-
reported AD, which has not been directly validated in ALSPAC,
but has been shown to be a reasonable predictor in other con-
texts, including validation by physical exam in the UK26 and
physician assessment in a multicentre US study.27 Missing data
could have introduced bias into our estimates, although we
tried to minimize this risk with FIML estimation and multiple
imputation techniques. There is uncertainty in phenotype
assignment that could affect regression results; however, we
compared several methods of accounting for it and found little
difference in our results, suggesting insensitivity to this issue.
Finally, there are few data sources recording AD severity, and
we were unable to find a large cohort with similarly character-
ized children to externally validate our findings, although we
did attempt this using a small cohort (Figure S9; see Support-
ing Information).
The LCA method involves probabilistic classification into
subgroups and individual disease trajectories can vary within
subgroups. For example, on average, active disease becomes
less likely over time in the Moderate–Declining group, but an
individual classified into this phenotype may still have active
FD in late childhood. Future work may consider how early
aggressive treatment for severe AD might modify the natural
history.28
Our study adds important information about patterns of AD
severity over time. The identified phenotypes were stable
across sensitivity analyses and had strong genetic associations,
providing support for using them in future work towards a
better aetiological understanding of AD, including the role of
environmental risk factors throughout the life course, and
towards better clinical trial design. Additional research is
underway to determine the utility of our phenotypes for prog-
nosis and to inform priorities for early intervention.
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